Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Acute Coronary Syndrome Market?

The market size of acute coronary syndrome has seen robust growth over the last few years. It is projected to increase from $9.86 billion in 2024 to $10.5 billion in 2025, displaying a compound annual growth rate (CAGR) of 6.5%. The significant growth during the historical period can be credited to public health campaigns, the integration of telemedicine and remote monitoring, enhanced emergency medical services, and the rising demand for patient education.

What Growth Rate Is Forecasted for the Acute Coronary Syndrome Market by 2029?

The market size for acute coronary syndrome is poised to experience remarkable growth in the coming years, with estimates projecting it to reach $13.3 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.1%. This expansion in the forecast period can be credited to factors such as the rising demand for personalized healthcare, growth in interventional cardiology practices, heightened awareness and the worldwide increase in the aging population. Key trends expected to emerge in the forecast period encompass advancements in the development of diagnostic tools, the incorporation of health information technology, swift response systems, and technological progressions.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12985&type=smp

Which Key Companies Are Shaping the Future of the Acute Coronary Syndrome Market?

Major companies operating in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.

Which Factors Are Driving Demand in the Acute Coronary Syndrome Industry?

A rise in chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases is anticipated to boost the acute coronary syndrome market’s growth. Ischemic heart disease, a type of chronic disease, is caused by the narrowing or blockage of the coronary arteries. The aim of acute coronary syndrome (ACS) treatment is to quickly alleviate symptoms, prevent heart damage, and avert further complications for patients with different forms of acute coronary syndromes, including ischemic heart disease and vascular diseases. A study published in the Journal of the American College of Cardiology in August 2022 by a US organization showed that all four cardiovascular risk factors are expected to increase within the general U.S. population between 2025 and 2060. Dyslipidemia and hypertension are set to rise by 27.6% and 25.1% respectively. The study found that heart failure (33.4%) and ischemic heart disease (30.7%) would experience the largest projected increases in rates, followed by heart attack (16.9%) and stroke (33.8%). Consequently, the persistent prevalence of chronic diseases such as coronary artery disease, ischemic heart disease, and vascular diseases is driving the acute coronary syndrome market. Driving the Acute Coronary Syndrome Market: Increased Healthcare Expenditures Encourage Advancement in Coronary Syndrome Care

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12985&type=smp

How Is the Acute Coronary Syndrome Market Segmented by Several Divisions?

The acute coronary syndrome market covered in this report is segmented –

1) By Type: Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, Unstable Angina

2) By Treatment: Medications, Statins, Beta blockers, ACE inhibitors, Anticoagulants, Other Treatment

3) By Diagnosis: Stress Test, Blood Tests, Imaging, Other Diagnosis

4) By Route Of Administration: Oral, Parenteral

5) By End-User: Hospitals, Specialty clinics, Other End User

Subsegments:

1) By Non-ST-Elevation Myocardial Infarction: Medical Management, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG)

2) By ST-Elevation Myocardial Infarction: Medical Management, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG)

3) By Unstable Angina: Medical Management, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG)

What are the Emerging Market Trends Driving the Growth of the Acute Coronary Syndrome Industry?

In an effort to maintain their market presence in the acute coronary syndrome sector, leading corporations are creating innovative medications. These developments in drug research could enhance the effectiveness of ACS treatment and minimize the resources and time needed for each patient. For instance, in June 2023, AGEPHA Pharma USA LLC, a US pharmaceutical firm, launched the FDA-approved Lodoco. This is a pioneering anti-inflammatory atheroprotective heart treatment, which reduces the risk of heart stroke, coronary revascularization, myocardial infarction (MI), and cardiovascular death among adult patients with cardiovascular diseases, including acute coronary syndrome.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Which Regions Are Driving Growth in the Acute Coronary Syndrome Market?

North America was the largest region in the acute coronary syndrome market in 2024. The regions covered in acute coronary syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12985

This Report Delivers Insight On:

1. How big is the acute coronary syndrome market, and how is it changing globally?

2. Who are the major companies in the acute coronary syndrome market, and how are they performing?

3. What are the key opportunities and risks in the acute coronary syndrome market right now?

4. Which products or customer segments are growing the most in the acute coronary syndrome market?

5. What factors are helping or slowing down the growth of the acute coronary syndrome market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model